Table 3.

Likert scale questions relating to the general care of haemophilia patients with inhibitors.

Question	Percentage agreement/disagreement (%)	Number of participants’ responses included in analysis (n)a	Delphi survey round
Joint health should be regularly measured in routine comprehensive care visits by a suitably trained physiotherapist using a validated tool	90.2	41	Round 1
Infusion requirements (both volume and frequency) must be considered when selecting a therapyb	84.4	32	Round 2
Quality of life should be regularly measured in routine comprehensive care visits using a validated tool	82.9	41	Round 1
The number of major bleeds should be specifically considered when deciding whether to offer prophylaxis with bypassing agents to a mild or moderate haemophilia patients with inhibitorsc	82.4	34	Round 2
Inadequate response to ITI is best defined as an upward trend in inhibitor titre or <20% reduction in inhibitor titre over a 6-month periodb	82.1	28	Round 2
The number of joint bleeds should be specifically considered when deciding whether to offer prophylaxis with bypassing agents to a mild or moderate haemophilia patient with inhibitorsc	79.4	34	Round 2
If inadequate response to ITI is observed at <200 IU/kg/day, the dose can be increased to this levelb	79.3	29	Round 2
The avoidance of allergic reactions is a key factor which should be considered when selecting a therapy	70.7	41	Round 1
The aims of treatment in haemophilia patients with inhibitors are completely different from the aims of treatment in haemophilia patients without inhibitors [b]	67.6	34	Round 2
Eradicating inhibitors is a priority in mild or moderate haemophilia patients with inhibitorsb	62.5	32	Round 2
Anamnesis is an important consideration when selecting a therapy prior to ITI or during ITIb	60.0	30	Round 2
Anamnesis is an important consideration when selecting a therapy for a patient who has failed ITIb	56.7	30	Round 2
Moderate haemophilia patients with inhibitors should not be routinely offered prophylaxis with bypassing agentsb	46.9	32	Round 2
For patients who inadequately respond to ITI, ITI should be terminatedd	43.3	30	Round 2
Infusion requirements should be specifically considered when deciding whether to offer prophylaxis with bypassing agents to a mild or moderate haemophilia patients with inhibitorsb	42.4	33	Round 2
Baseline factor activity levels should be specifically considered when deciding whether to offer prophylaxis with bypassing agents to a mild or moderate haemophilia patients with inhibitorsb	37.9	29	Round 2
Mild haemophilia patients with inhibitors should not be routinely offered prophylaxis with bypassing agentsb	37.9	29	Round 2

A total of 41 participants answered questions on general care in Round 1, and 34 in Round 2. Questions achieving consensus agreement and disagreement (⩾70% participants agreeing/disagreeing with the statement) are highlighted in dark blue and light blue, respectively. Where questions did not achieve consensus in Round 1 and were carried forward to Round 2, only the Round 2 results are shown here.

^aIn Round 2, ‘IE’ responses were removed prior to analysis.

^bRephrased from question in Round 1.

^cNew question added based on free-text response in Round 1.

^dRound 1 question restated in Round 2.

IE, insufficient expertise; ITI, immune tolerance induction; IU, international units.